Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: SkyQuest | PRODUCT CODE: 1899964

Cover Image

PUBLISHER: SkyQuest | PRODUCT CODE: 1899964

Therapeutic Vaccines Market Size, Share, and Growth Analysis, By Products (Addiction Vaccines, Autoimmune Disease Vaccines), By Technology (Autologous vaccines, Allogeneic vaccines), By Region - Industry Forecast 2026-2033

PUBLISHED:
PAGES: 215 Pages
DELIVERY TIME: 3-5 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5300
PDF & Excel (Multiple User License)
USD 6200
PDF & Excel (Enterprise License)
USD 7100

Add to Cart

Global Therapeutic Vaccines Market size was valued at USD 59.35 Billion in 2024 and is poised to grow from USD 65.58 Billion in 2025 to USD 145.77 Billion by 2033, growing at a CAGR of 10.5% during the forecast period (2026-2033).

The therapeutic vaccines market is experiencing significant growth as these vaccines are administered to enhance immune responses in patients undergoing treatment for chronic diseases, thereby improving recovery prospects. The increasing prevalence of chronic illnesses, coupled with heightened investments in research and development of innovative vaccines, is expected to drive market expansion. Additionally, there is a rising awareness of preventive healthcare and a growing preference for personalized medicine on a global scale, which further fuels demand for therapeutic vaccines. However, challenges such as the complex R&D processes and limited efficacy may hinder long-term market development. To create new opportunities, therapeutic vaccine companies can explore integration with various immunotherapies and precision medicine strategies in the evolving healthcare landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Therapeutic Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Therapeutic Vaccines Market Segments Analysis

Global Therapeutic Vaccines Market is segmented by Products, Technology and region. Based on Products, the market is segmented into Addiction Vaccines, Autoimmune Disease Vaccines, Infectious Disease Vaccines and Neurological Disease Vaccines. Based on Technology, the market is segmented into Autologous vaccines and Allogeneic vaccines. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Therapeutic Vaccines Market

The rising prevalence of infectious and chronic diseases globally has heightened public awareness of preventive healthcare, leading to an increased focus on innovative solutions such as therapeutic vaccines. This growing recognition of the importance of disease prevention is expected to drive demand for therapeutic vaccines, as individuals and healthcare systems alike seek effective measures to combat various health challenges. As more people prioritize vaccination as a proactive approach to health management, the therapeutic vaccines market stands poised for substantial growth, reflecting the evolving landscape of healthcare priorities and the collective push towards improved health outcomes for populations worldwide.

Restraints in the Global Therapeutic Vaccines Market

The Global Therapeutic Vaccines market faces significant constraints due to the stringent approval and testing processes these vaccines must navigate prior to being available for patient use globally. The involved procedures require extensive evaluation and can be both lengthy and intricate, resulting in delays that hinder the prompt introduction of new therapies to the market. This protracted timeline ultimately restricts the growth potential of the market, as the slow pace of product approval can stall innovation and limit the availability of potentially groundbreaking treatments for patients in need.

Market Trends of the Global Therapeutic Vaccines Market

The Global Therapeutic Vaccines market is experiencing a notable trend towards the integration of innovative immunotherapy approaches, particularly for cancer treatment. Vendors are increasingly focusing on the development of specialized therapeutic vaccines tailored to modulate immune responses specific to various tumors. This strategic pivot aims to enhance the efficacy rates of existing immunotherapies, providing more personalized and effective treatment options for patients. As understanding of tumor immunology advances, the market is poised for growth, driven by the need for improved targeted therapies that leverage the body's immune system to combat cancer more effectively.

Product Code: SQMIG35J2111

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2025
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis

Global Therapeutic Vaccines Market Size by Products & CAGR (2026-2033)

  • Market Overview
  • Addiction Vaccines
  • Autoimmune Disease Vaccines
  • Infectious Disease Vaccines
  • Neurological Disease Vaccines

Global Therapeutic Vaccines Market Size by Technology & CAGR (2026-2033)

  • Market Overview
  • Autologous vaccines
  • Allogeneic vaccines

Global Therapeutic Vaccines Market Size & CAGR (2026-2033)

  • North America (Products, Technology)
    • US
    • Canada
  • Europe (Products, Technology)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Products, Technology)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Products, Technology)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Products, Technology)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • GlaxoSmithKline plc (GSK) (United Kingdom)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi S.A. (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Moderna, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BioNTech SE (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bavarian Nordic A/S (Denmark)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Medigene AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Arbutus Biopharma Corporation (Canada)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Inovio Pharmaceuticals, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Dynavax Technologies Corporation (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Agenus Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Heat Biologics, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Northwest Biotherapeutics, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • ImmunoCellular Therapeutics, Ltd. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Advaxis, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • OncoSec Medical Incorporated (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Vical Incorporated (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Celldex Therapeutics, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Altimmune, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!